伊立替康联合顺铂方案治疗复治性晚期小细胞肺癌23例临床观察  

The Clinical Observation of Combined Chemotherapy of Irinotecan and Cisplatin in the Treatment of Relapsed Advanced Small Cell Lung Cancer

作　　者：任中海[1] 张成辉[1] 李明[1] 

机构地区：[1]南阳市中心医院肿瘤科,河南南阳473000

出　　处：《肿瘤基础与临床》2008年第2期138-140,共3页journal of basic and clinical oncology

摘　　要：目的观察伊立替康联合顺铂方案治疗复治性晚期小细胞肺癌的疗效和安全性。方法伊立替康联合顺铂治疗23例复发或进展的小细胞肺癌,伊立替康60 mg/m2静脉滴注,d1,8,15,DDP 60 mg/m2静脉滴注,d1;每28 d为1个周期。结果23例均可评价疗效,完全缓解率为13%(3/23),部分缓解率为30.4%(7/23),总有效率CR+PR为43.5%;稳定6例(26.1%),进展7例(30.4%),中位疾病进展时间为4.6个月,中位生存期为8.3个月。主要毒副反应为血液学毒性和消化道症状,其中Ⅲ、Ⅳ度白细胞减少发生率为65.2%(15/23);血小板减少发生率为34.8%(8/23);恶心呕吐发生率为82.6%(19/23);腹泻发生率较高,为87.0%(20/23),其中Ⅲ、Ⅳ度腹泻为56.5%(13/23)。全组无毒性相关死亡。结论伊立替康联合顺铂作为二线方案治疗复治性晚期小细胞肺癌有较好的疗效,毒副反应可以耐受。Objective The aim of this study is to evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced SCLC. Methods Eligible patients with SCLC who had progressed or relapsed after therapy were done with cisplatin and irinotecan. The regimen consisted of irinotecan 60 mg/m^2 on d1,8,15 and cisplatin 60 mg/m^2 on d1 ; the plan was given every 28 days. Results In 23 evaluable patients, responses included 5 complete remissions and 7 partial remissions （ overall response rate, 43.5% ） , 6 patients had stable disease and 7 had progressive disease. Median time to progression and median survival were 4.6 and 8.3 months, the main toxicity was the matological toxicity, nausea and vomiting. Grade m, leukopenia was seen in 15 patients （65.2%） , thrombocytopenia was seen in 8 patients （34.8%） ; Nausea and vomiting was seen in 19 patients （82.6%） ; Grade Ⅲ, Ⅳ nausea and vomiting was seen in 4 patients （65.2%） , diarrhea was seen in 20 patients （87.0%） . There were no treatment-related death. Conclusions The combination of irinotecan and cisplatin is highly active and tolerable in patients with relapsed SCLC when it is administered as second-line treatment.

关 键 词：伊立替康 顺铂 小细胞肺癌 联合化疗 

分 类 号：H734.2[语言文字] R730.53[医药卫生—肿瘤]